kymera
therapeutics
present
data
novel
irakimid
protein
degraders
virtual
american
society
hematology
ash
annual
meeting
nasdaq
kymr
watertown
globe
newswire
kymera
therapeutics
nasdaq
kymr
biopharmaceutical
company
advancing
targeted
protein
degradation
deliver
novel
small
molecule
protein
degrader
therapeutics
today
announced
company
present
new
preclinical
data
irakimid
degrader
programs
american
society
hematology
ash
annual
meeting
taking
place
virtually
excited
share
first
time
preclinical
data
irakimid
development
candidate
formerly
well
expanded
preclinical
investigation
degrader
program
allowed
us
uncover
important
insights
therapeutic
potential
across
variety
hematologic
cancers
said
jared
gollob
md
chief
medical
officer
kymera
therapeutics
results
also
establish
potential
intermittent
dosing
schedules
programs
guide
advancement
clinic
next
year
irakimid
program
abstract
novel
irakimid
degrader
imid
substrates
shows
preferential
activity
induces
regressions
dlbcl
cdx
pdx
models
presented
duncan
walker
phd
vice
president
oncology
kymera
therapeutics
poster
session
ii
sunday
pm
pt
abstract
targeting
dlbcl
irakimids
comparison
kinase
inhibition
evaluation
synergy
rational
combinations
presented
jennifer
lue
md
columbia
university
irving
medical
center
poster
session
iii
monday
pm
pt
data
presented
show
deep
sustained
tumor
regression
intermittent
dosing
dlbcl
well
tolerated
exhibited
potent
sustained
antitumor
activity
multiple
mouse
cdx
pdx
models
dlbcl
across
range
po
iv
intermittent
dosing
schedules
well
tolerated
exhibited
potent
sustained
antitumor
activity
multiple
mouse
cdx
pdx
models
dlbcl
across
range
po
iv
intermittent
dosing
schedules
preferential
activity
dlbcl
irrespective
mutation
activity
specific
cell
lines
relative
wt
cell
lines
independent
variety
common
activate
pathways
activity
specific
cell
lines
relative
wt
cell
lines
independent
variety
common
activate
pathways
superiority
imids
kinase
inhibitor
models
dlbcl
irakimids
showed
superior
cell
killing
compared
either
imids
kinase
inhibitor
alone
models
dlbcl
irakimids
showed
superior
cell
killing
compared
either
imids
kinase
inhibitor
alone
synergistic
combination
potential
rational
combinations
irakimids
either
btk
inhibitors
showed
synergistic
vitro
activity
dlbcl
program
abstract
mechanisms
activity
degraders
lymphoma
presented
haojing
rong
phd
vice
president
development
poster
session
ii
sunday
pm
pt
data
presented
show
tumor
regressions
alcl
intermittent
dosing
weekly
dosing
achieved
complete
tumor
regressions
doses
lowered
tumor
levels
maintained
lowering
days
weekly
dosing
achieved
complete
tumor
regressions
doses
lowered
tumor
levels
maintained
lowering
days
antitumor
mechanism
action
proteomics
showed
degradation
vitro
alcl
associated
inhibition
cytokine
signaling
cell
cycle
arrest
induction
apoptosis
findings
build
results
reported
american
association
cancer
research
aacr
virtual
annual
meeting
ii
highlighted
potent
effects
kymera
selective
irakimid
degraders
multiple
animal
models
cancer
kymera
therapeutics
kymera
therapeutics
biopharmaceutical
company
focused
transformative
new
approach
address
previously
intractable
disease
targets
kymera
advancing
field
targeted
protein
degradation
accessing
body
innate
protein
recycling
machinery
degrade
dysregulated
proteins
kymera
pegasus
targeted
protein
degradation
platform
harnesses
body
natural
protein
recycling
machinery
degrade
proteins
focus
nodes
validated
pathways
currently
inaccessible
conventional
therapeutics
kymera
accelerating
drug
discovery
unmatched
ability
target
degrade
intractable
proteins
advance
new
treatment
options
patients
kymera
initial
programs
target
irakimid
within
tlr
jak
stat
pathways
providing
opportunity
treat
broad
range
diseases
hematologic
malignancies
solid
tumors
information
visit
kymera
therapeutics
proprietary
protein
degradation
platform
created
team
experienced
drug
hunters
improve
effectiveness
targeted
protein
degradation
generate
pipeline
novel
therapeutics
previously
undruggable
diseases
platform
consists
informatics
driven
target
identification
novel
ligases
proprietary
ternary
complex
predictive
modeling
capabilities
degradation
tools
cautionary
note
regarding
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
implied
express
statements
regarding
strategy
business
plans
objectives
irakimid
degrader
programs
plans
timelines
clinical
development
kymera
therapeutics
product
candidates
including
therapeutic
potential
clinical
benefits
thereof
words
may
might
could
would
expect
plan
anticipate
intend
believe
estimate
seek
predict
future
project
potential
continue
target
similar
words
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
risks
associated
impact
countries
regions
operations
business
well
timing
anticipated
results
current
preclinical
studies
future
clinical
trials
strategy
future
operations
delay
current
preclinical
studies
future
clinical
trials
development
kymera
therapeutics
drug
candidates
risk
results
current
preclinical
studies
may
predictive
future
results
connection
future
clinical
trials
kymera
therapeutics
ability
successfully
demonstrate
safety
efficacy
drug
candidates
timing
outcome
company
planned
interactions
regulatory
authorities
obtaining
maintaining
protecting
intellectual
property
risks
uncertainties
described
greater
detail
section
entitled
risk
factors
quarterly
report
form
period
ended
septmeber
filed
november
well
discussions
potential
risks
uncertainties
important
factors
kymera
therapeutics
subsequent
filings
securities
exchange
commission
addition
statements
represent
kymera
therapeutics
views
today
relied
upon
representing
views
subsequent
date
kymera
therapeutics
explicitly
disclaims
obligation
update
statements
representations
warranties
expressed
implied
made
accuracy
statements
contact
investors
bruce
jacobs
chief
financial
officer
christopher
brinzey
westwicke
icr
company
kymera
therapeutics
media
lissette
steele
verge
scientific
communications
kymera
therapeutics
lsteele
